eli lilly retatrutide press release 2024 2025 Lilly's triple-acting obesity drug hits goal in Phase 3 trial Eli Lilly's retatrutide sets new

Although liraglutide is the most studied GLP-1 agonist in psychiatric patients and is available in a generic form, it requires daily dosing and is less effective than the branded, once-weekly GLP-1 agonists semaglutide and tirzepatide.

Core+ is ideal if youre already taking GLP1s elsewhere and want structured nutrition and lifestyle support

Body recomposition, which means losing fat while maintaining or building lean muscle, is a fundamentally different physiological process than rapid weight reduction

Gastroenterology, 152(7), 17181727.e3

They lose lean muscle mass and regain the weight, risking conditions like sarcopenic obesity, leaving them potentially worse off than before they started the medication